WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:
Date: | Wednesday, November 13, 2024 |
Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
Toll Free: | 1-844-825-9789 |
International: | 1-412-317-5180 |
Conference ID: | 10193688 |
Call Me Link: | https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1693210&tp_key=d77879d241 |
Please call the conference telephone number or log on to the web access link five minutes prior to the start time.
A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at http://www.optimizerx.com/investors.
About OptimizeRx
OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care network, OptimizeRx is changing the way life sciences engages with customers.
For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.40 |
Daily Change: | -0.03 -0.55 |
Daily Volume: | 103,411 |
Market Cap: | US$99.470M |
December 23, 2024 November 13, 2024 September 09, 2024 August 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load